Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product
Kamada Ltd. - Ordinary Shares (KMDA)
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
kamada.com/investors.php
Company Research
Source: GlobeNewswire
Commercial supply of the 12-year contract manufacturing agreement, following the completion of the required tech-transfer project, is expected to commence in early 2023Based on current market sales volume, the new product is estimated to add approximately $8 million to $10 million in annual revenues to KamadaGross margin level of the new product is anticipated to be similar to average gross margins of the Company’s proprietary products segment REHOVOT, Israel, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture a U.S. Food and Drug Administration (FDA) approved and commercialized specialty hyper-immune globulin product. Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals,
Show less
Read more
Impact Snapshot
Event Time:
KMDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KMDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KMDA alerts
High impacting Kamada Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KMDA
News
- Kamada Ltd. (NASDAQ: KMDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ... [Yahoo! Finance]Yahoo! Finance
- Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability GuidanceGlobeNewswire
- Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024GlobeNewswire
- Kamada to Present at the Stifel 2024 Healthcare ConferenceGlobeNewswire
KMDA
Earnings
- 11/13/24 - In-Line
KMDA
Analyst Actions
- 11/14/24 - HC Wainwright
KMDA
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 6-K
- 11/6/24 - Form 6-K
- KMDA's page on the SEC website